Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

Snydman, DR; McDermott, LA; Thorpe, CM; Chang, J; Wick, J; Walk, ST; Vickers, RJ

Snydman, DR (reprint author), Tufts Med Ctr, 800 Washington St,Box 238, Boston, MA 02111 USA.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018; 73 (8): 2078

Abstract

Objectives: We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索